Nanotechnology-based combinatorial anti-glioblastoma therapies: moving from terminal to treatable
Aggressive glioblastoma (GBM) has no known treatment as a primary brain tumor. Since the cancer is so heterogeneous, an immunosuppressive tumor microenvironment (TME) exists, and the blood–brain barrier (BBB) prevents chemotherapeutic chemicals from reaching the central nervous system (CNS), therape...
Saved in:
Main Authors: | Barzegar Behrooz, Amir, Talaie, Zahra, Syahir, Amir |
---|---|
Format: | Article |
Published: |
Multidisciplinary Digital Publishing Institute
2022
|
Online Access: | http://psasir.upm.edu.my/id/eprint/102279/ https://www.mdpi.com/1999-4923/14/8/1697# |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Could we address the interplay between CD133, Wnt/β-Catenin, and TERT signaling pathways as a potential target for Glioblastoma therapy?
by: Behrooz, Amir Barzegar, et al.
Published: (2021) -
Understanding glioblastoma biomarkers: knocking a mountain with a hammer
by: Mesrati, Malak Hassn, et al.
Published: (2020) -
Treatable myopathies
by: Goh, Khean Jin
Published: (2021) -
Anaerobic treatability of distillery spentwash
by: Isa, M.H., et al.
Published: (1999) -
Treatability of leachate using EZ enzyme
by: Ithnin, Masliana
Published: (2011)